What Does the Recent Thalassemia Approval Mean for Agios Pharmaceuticals

Related Articles

What Does NRx Pharmaceuticals' Recent $22.3 Million Offering Mean for Investors

3 months ago

What Does FERC Approval Mean for the TXNM Energy-Blackstone Deal

6 months ago

What Does YUVIWEL's FDA Approval Mean for Ascendis Pharma

6 months ago

What Does EPA Approval Mean for BioProtect Solutions' Market Trajectory

4 months ago

Category

You may also like

Stock News•2 weeks ago

Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel

Agios' mitapivat revenue rose 259% YoY to $44.7M in Q2 2026, driven by the thalassemia launch. The $965M cash position funds pipeline expansion ahead of the November 1, 2026, PDUFA for sickle cell dis...

AGIO

Share

Stock News•2 weeks ago

Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of Gene Therapy for Glycogen Storage Disease Type 1a Transcript

Ultragenyx's gene therapy for glycogen storage disease type 1a received FDA approval, marking a key regulatory milestone. The approval could drive revenue growth if commercial launch executes well.

RARE

Share

Stock News•1 months ago

Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?

Agios Pharmaceuticals (AGIO) shares jumped 17.7% on above-average volume, but earnings estimate revisions do not suggest further strength ahead.

AGIO

Share